The Challenge: Most biologic drugs are monoclonal antibodies, which are notoriously hard to crystallize on Earth. Structural studies of macromolecules help refine the design, production, administration, and storage of critical pharmaceuticals. However, many molecules
are difficult or impossible to crystallize in traditional laboratory settings. Advances in the crystallization of monoclonal antibody drugs could translate into significant improvements in quality of life for patients with cancer and autoimmune disorders.
To access this report, please enter the information below:
